Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Gamma-aminobutyric acid type A (GABAA) receptor is a heteropentameric ligand-gated chloride channel that serves as the primary mediator of rapid inhibitory neurotransmission in the mammalian central nervous system [1: Sigel & Steinmann, 2012, J Biol Chem]. Receptors composed of alpha1, alpha2, alpha3, or alpha5 subunits alongside a gamma2 subunit are of particular clinical importance because they form the high-affinity binding site for benzodiazepines at the alpha/gamma2 subunit interface [2: Rudolph & Knoflach, 2011, Nat Rev Drug Discov]. The alpha1-containing receptors are widely expressed and primarily mediate sedative, amnestic, and anticonvulsant activities, whereas alpha2 and alpha3 subtypes are localized in the limbic system and spinal cord, mediating anxiolytic and muscle-relaxant effects [3: Möhler, 2006, J Recept Signal Transduct Res]. The alpha5-containing receptors are predominantly found in the hippocampus and are involved in learning and memory processes [4: Sieghart & Savic, 2018, Pharmacol Rev]. These receptor subtypes are key therapeutic targets for treating anxiety, insomnia, and epilepsy, though non-selective modulation is often limited by side effects such as ataxia and the potential for dependence [5: Atack, 2003, Curr Drug Targets CNS Neurol Disord]. Pharmacological research continues to focus on developing subtype-selective ligands to isolate desired therapeutic effects from adverse reactions.
Positive allosteric modulation at the benzodiazepine binding site, which is located at the interface between the alpha (1, 2, 3, or 5) and gamma2 subunits; this modulation increases the frequency of chloride channel opening in response to GABA binding, thereby enhancing inhibitory neurotransmission [1: Sigel & Steinmann, 2012, J Biol Chem].
9 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Gamma-aminobutyric acid type A receptor (GABAA receptor) containing alpha1, alpha2, alpha3, or alpha5 and gamma2 subunits (GABAA receptor (alpha1/2/3/5, gamma2)).